Zentalis Pharmaceuticals (ZNTL) AI Stock Analysis

• Market Cap: $148.96M
• Dividend Yield: N/A
• Average Volume (3M): 716.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.57
• Revenue Growth: -33.76%
• EPS Growth: 17.54%
• Country: US
• Employees: 166
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 70,931,015
• 10 Day Avg. Volume: 819,524
• 30 Day Avg. Volume: 716,917
• PEG Ratio: 0.04
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.77
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -370.82
• Enterprise Value/Ebitda: -1.14
• 1Y Price Target: $6.60
• Price Target Upside: 368.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -1.86
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $2.50 ▲(77.30% Upside)
• Action: Reiterated Date: 03/27/26
• Date: Action: Reiterated 03/27/26

The score is held back primarily by weak financial performance (ongoing losses, cash burn, and shrinking equity). Technicals are modestly supportive with price above major moving averages and neutral momentum, while corporate updates provide constructive clinical and runway catalysts. Valuation remains constrained by negative earnings and no dividend data.

Positive Factors

Regulatory alignment & Phase‑3 path

FDA alignment on trial design materially lowers regulatory execution risk and creates a clear registrational pathway for azenosertib. This durable milestone clarifies endpoints, timelines and data requirements, improving the probability of a coherent development plan and partner interest.

Negative Factors

Persistent negative cash flow

Sustained negative operating and free cash flow forces dependence on external financing to fund development. Over the medium term this raises dilution and execution risk if additional capital is needed before value‑creating milestones, constraining strategic flexibility.

Zentalis Pharmaceuticals Business Overview & Revenue Model

Company Description

Zentalis Pharmaceuticals (ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company operates in the biotechnology sector,...

Read more

Zentalis Pharmaceuticals (ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company operates in the biotechnology sector,...

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Zentalis has not historically generated meaningful recurring revenue from commercial product sales and generally does not rely on an established marketed-product business. Instead, its funding typical...

Read more

As a clinical-stage biopharmaceutical company, Zentalis has not historically generated meaningful recurring revenue from commercial product sales and generally does not rely on an established marketed-product business. Instead, its funding typical...

Zentalis Pharmaceuticals Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	67.42M	0.00	0.00	0.00
Gross Profit	-739.00K	67.42M	0.00	0.00	0.00
EBITDA	-145.51M	-186.17M	-247.60M	-225.86M	-207.20M
Net Income	-137.06M	-165.84M	-292.19M	-236.81M	-158.72M
Balance Sheet
Total Assets	288.97M	430.34M	562.03M	553.46M	472.02M
Cash, Cash Equivalents and Short-Term Investments	245.89M	371.08M	482.92M	437.37M	340.13M
Total Debt	39.58M	42.65M	45.77M	47.33M	45.91M
Total Liabilities	72.76M	93.15M	124.64M	119.43M	107.54M
Stockholders Equity	216.20M	337.19M	437.28M	433.80M	363.95M
Cash Flow
Free Cash Flow	-125.25M	-171.08M	-208.41M	-166.30M	-160.20M
Operating Cash Flow	-125.25M	-170.86M	-207.82M	-163.75M	-154.09M
Investing Cash Flow	131.62M	176.56M	-44.46M	-114.18M	-18.11M
Financing Cash Flow	-4.28M	108.00K	237.30M	261.04M	178.52M

Zentalis Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.41
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZNTL, the sentiment is Negative. The current price of 1.41 is below the 20-day moving average (MA) of 2.56, below the 50-day MA of 2.58, and below the 200-day MA of 1.80, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 38.70 is Neutral, neither overbought nor oversold. The STOCH value of 31.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZNTL.

Zentalis Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZNTL	53 Neutral	$148.96M	-0.69	-57.49%	―	-33.76%	17.54%
SPRO	53 Neutral	$134.89M	15.23	22.53%	―	-67.38%	-1076.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	47 Neutral	$331.97M	-0.70	―	―	-63.96%	-28.50%
VTGN	45 Neutral	$22.56M	-0.37	―	―	-33.00%	54.91%
MGNX	43 Neutral	$186.22M	-1.36	-120.20%	―	-9.70%	23.23%
ANIX	―	$85.50M	-9.85	-65.55%	―	―	11.78%

Zentalis Pharmaceuticals Corporate Events